Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of exacerbations in asthma or in chronic obstructive pulmonary disease (COPD) are often modeled by negative binomial distributions. In this manuscript, we study planning and analyzing clinical trials with group sequential designs for negative binomial outcomes. We propose a group sequential testing procedure for negative binomial outcomes based on Wald statistics using maximum likelihood estimators. The asymptotic distribution of the proposed group sequential test statistics is derived. The finite sample size properties of the proposed group sequential test for negative binomial outcomes and the methods for planning the respective clinical trials are assessed in a simulation study. The simulation scenarios are motivated by clinical trials in chronic heart failure and relapsing multiple sclerosis, which cover a wide range of practically relevant settings. Our research assures that the asymptotic normal theory of group sequential designs can be applied to negative binomial outcomes when the hypotheses are tested using Wald statistics and maximum likelihood estimators. We also propose two methods, one based on Student’s t-distribution and one based on resampling, to improve type I error rate control in small samples. The statistical methods studied in this manuscript are implemented in the R package gscounts, which is available for download on the Comprehensive R Archive Network (CRAN).
Jennison C and Turnbull BW. Group sequential designs with applications to clinical trials. Boca Raton, Florida, USA: Chapman & Hall/CRC, 2000.
2.
ShobenABEmersonSS. Violations of the independent increment assumption when using generalized estimating equation in longitudinal group sequential trials. Stat Med2014; 33: 5041–5056.
3.
WhiteheadJ. The design and analysis of sequential clinical trials, West Sussex, England: John Wiley & Sons, 1997.
4.
Wassmer G and Brannath W. Group sequential and confirmatory adaptive designs in clinical trials. Heidelberg, Germany: Springer, 2016.
5.
SormaniMPBruzziPMillerDH, et al.Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci1999; 163: 74–80.
6.
KeeneONJonesMRKLanePW, et al.Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharmaceut Stat2007; 6: 89–97.
7.
KeeneONCalverleyPMAJonesPW, et al.Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J2008; 32: 17–24.
8.
KeeneONVestboJAndersonJ, et al.Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J2009; 34: 1018–1023.
9.
Rodés-CabauJHorlickEIbrahimR, et al.Effect of clopidogrel and aspirin vs aspirin alone on migraine headaches after transcatheter atrial septal defect closure: the CANOA randomized clinical trial. J Am Med Assoc2015; 314: 2147–2154.
10.
SchlesingerNMyslerELinHY, et al.Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheumat Dis2011; 70: 1264–1271.
11.
RogersJKPocockSJMcMurrayJJV, et al.Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Failure2014; 16: 33–40.
12.
CookRJLawlessJF. Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics1996; 52: 1311–1323.
13.
CookRJFarewellVT. Incorporating surrogate endpoints into group sequential trials. Biometric J1996; 38: 119–130.
14.
JiangW. Group sequential procedures for repeated events data with frailty. J Biopharmaceut Stat1999; 9: 379–399.
15.
XiaQHooverDR. A procedure for group sequential comparative Poisson trials. J Biopharmaceut Stat2007; 16: 869–881.
16.
CookRJGraceYYLeeKA. Sequential testing with recurrent events over multiple treatment periods. Stat Biosci2010; 2: 137–153.
17.
PonikowskiPVoorsAAAnkerSD, et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Failure2016; 18: 891–975.
18.
Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for the treatment of chronic heart failure, https://goo.gl/HHgONb (accessed 20 October 2016).
19.
RogersJKMcMurrayJJVPocockSJ, et al.Eplerenone in patients with systolic heart failure and mild symptoms analysis of repeat hospitalizations. Circulation2012; 126: 2317–2323.
20.
RogersJKJhundPSPerezAC, et al.Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure2014; 2: 289–297.
21.
UdelsonJE. Heart failure with preserved ejection fraction. Circulation2011; 124: 540–543.
22.
RedfieldMM. Heart failure with preserved ejection fraction. New Engl J Med2016; 375: 1868–1877.
23.
YusufSPfefferMASwedbergK, et al.Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003; 362: 777–781.
24.
MehtaCGaoPBhattDL, et al.Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation2009; 119: 597–605.
25.
JacksonNAtarDBorentainM, et al.Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur Heart J2016; 37: 747–754.
26.
CohenJARudickRA. Multiple sclerosis therapeutics, Cambridge, England: Cambridge University Press, 2011.
27.
SelmajKLiSKBHartungHP, et al.Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol2013; 12: 756–767.
28.
CookRJLawlessJ. The statistical analysis of recurrent events, New York, NY, USA: Springer Science & Business Media, 2007.
29.
LawlessJF. Negative binomial and mixed Poisson regression. Can J Stat1987; 15: 209–225.
30.
GalloPMaoLShihVH. Alternative views on setting clinical trial futility criteria. J Biopharmaceut Stat2014; 24: 976–993.
31.
ScharfsteinDOTsiatisAARobinsJM. Semiparametric efficiency and its implication on the design and analysis of group-sequential studies. J Am Stat Assoc1997; 92: 1342–1350.
32.
JennisonCTurnbullBW. Group-sequential analysis incorporating covariate information. J Am Stat Assoc1997; 92: 1330–1341.
33.
LanKKGDeMetsDL. Discrete sequential boundaries for clinical trials. Biometrika1983; 70: 659–663.
34.
ProschanMAFollmannDAWaclawiwMA. Effects of assumption violations on type I error rate in group sequential monitoring. Biometrics1992; 48: 1131–1143.
35.
AbanIBCutterGRMavingaN. Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data. Computat Stat Data Analys2009; 53: 820–833.
36.
FarringtonCPManningG. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med1990; 9: 1447–1454.
37.
TangNSTangMLWangSF. Sample size determination for matched-pair equivalence trials using rate ratio. Biostatistics2006; 8: 625–631.
38.
MützeTMunkAFriedeT. Design and analysis of three-arm trials with negative binomially distributed endpoints. Stat Med2016; 35: 505–521.
39.
PocockSJ. Group sequential methods in the design and analysis of clinical trials. Biometrika1977; 64: 191–199.
40.
MützeTKonietschkeFMunkA, et al.A studentized permutation test for three-arm trials in the ‘gold standard’ design. Stat Med2017; 36: 883–898.
41.
SpiessensBDeboisM. Adjusted significance levels for subgroup analyses in clinical trials. Contemporary Clin Trials2010; 31: 647–656.
42.
Placzek M and Friede T. Clinical trials with nested subgroups: analysis, sample size determination and internal pilot. Stat Meth Med Res 2017; 27: 3286–3303.
43.
Graf AC, Wassmer G, Friede T, et al. Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker. Stat Meth Med Res 2017 (submitted).
44.
Jennison C. Bootstrap tests and confidence intervals for a hazard ration when the number of observed failures is small, with applications to group sequential survival studies. In: Proceedings of the 22nd interface conference on computing science and statistics, Michigan, USA, May 1990, pp.89–97.
KieserMHauschkeD. Assessment of clinical relevance by considering point estimates and associated confidence intervals. Pharmaceut Stat2005; 4: 101–107.
47.
FischRJonesIJonesJ, et al.Bayesian design of proof-of-concept trials. Therapeut Innovat Regulat Sci2015; 49: 155–162.
48.
GsponerTGerberFBornkampB, et al.A practical guide to Bayesian group sequential designs. Pharmaceut Stat2014; 13: 71–80.
49.
Asendorf T, Henderson R, Schmidli H, et al. Modelling and sample size reestimation for longitudinal count data with incomplete follow up. (Submitted for publication).
50.
Committee for Medicinal Products for Human Use (CHMP). Guideline on adjustment for baseline covariates in clinical trials, https://goo.gl/YIJHEh (accessed 20 November 2016).
ScharfsteinDOTsiatisAA. The use of simulation and bootstrap in information-based group sequential studies. Stat Med1998; 17: 75–87.
53.
Mehta CR and Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Inform J 2001; 35: 1095–1112.
54.
ParmarMKBGriffithsGOSpiegelhalterDJ, et al.Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet2001; 358: 375–381.
55.
FriedeTSchmidliH. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Stat Med2010; 29: 1145–1156.
56.
FriedeTSchmidliH. Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials. Meth Inform Med2010; 49: 618–624.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
